Drs. Hossein Borghaei and Tony Calles dissect the pivotal abstracts and cutting-edge data unveiled at ESMO 2023, spotlighting the transformative landscape of lung cancer treatment. From exploring innovative immunotherapy combinations to the promising prospects of antibody-drug conjugates, they navigate through the complexities of neo-adjuvant and adjuvant sequencing, shedding light on optimal therapeutic strategies.
With a keen focus on targeted therapies and an array of other compelling studies, Drs. Borghaei and Calles decode the implications of these advancements, offering invaluable insights into reshaping the future of lung cancer care.
A great Healthcare Unfiltered episode with top lung cancer experts; not to be missed. As always, let me know what you think and don’t forget to hit the subscribe and like buttons – please do share with others as well.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
